Digital PCR pricing varies widely by instrument configuration, automation, throughput, consumables and service requirements. For buyers, comparing only the upfront instrument price can give a misleading picture of the actual investment.
See where companies are placing their bets, what customers are asking for and where the opportunity is opening up. Download Sample: https://www.towardshealthcare.com/download-sample/5367
Top Digital PCR Platforms and Pricing
| Company | Platform | Publicly listed price* | Key positioning |
|---|---|---|---|
| Thermo Fisher Scientific | QuantStudio Absolute Q | ₹96.96 lakh | Desktop dPCR, 16 samples/plate, 20,480 microchambers per sample |
| Thermo Fisher Scientific | Absolute Q AutoRun, single configuration | ₹1.99 crore | Automated workflow, up to 72 hours of unattended operation |
| Thermo Fisher Scientific | Absolute Q AutoRun, dual configuration | ₹2.76 crore | Two Absolute Q systems with automated plate movement |
| Bio-Rad | QX200 ddPCR | Quote-based | Established droplet-based ddPCR platform |
| Bio-Rad | QX600/QX700 family | Quote-based | Higher-throughput and multiplex ddPCR workflows |
*Prices shown are current publicly listed India prices where available. Bio-Rad generally uses quotation-based pricing, so direct price comparison should be treated carefully.
Thermo Fisher: From ₹96.96 Lakh to ₹2.76 Crore
Thermo Fisher provides one of the clearest public pricing examples.
The QuantStudio Absolute Q desktop system is listed at ₹9,696,062, approximately ₹96.96 lakh. It provides 16 reactions per plate, with each sample partitioned into 20,480 microchambers and results available in approximately 90 minutes.
For laboratories requiring automation, the price rises considerably.
The single-configuration AutoRun system is ₹1.99 crore, while the dual-configuration system is ₹2.76 crore. The dual system combines two Absolute Q instruments with automated plate movement and workflow scheduling.
This shows that automation can add a major capital cost, but it is designed for laboratories where higher utilization and reduced hands-on intervention justify the investment.
Bio-Rad: Quote-Based Pricing and Established ddPCR
Bio-Rad’s QX200 uses a droplet digital PCR workflow, while its newer QX600 and QX700 platforms extend the company’s ddPCR portfolio.
Unlike Thermo Fisher’s India website, Bio-Rad does not provide a comparable public instrument price, so buyers generally need to request a quotation.
For this reason, buyers should compare the complete system configuration, rather than assuming a quote for one Bio-Rad instrument is directly equivalent to Thermo Fisher’s published base-system price.
Consumables Can Change the Economics
The instrument is only the initial investment.
For example, Thermo Fisher lists its Absolute Q MAP16 Plate Kit with 1-Step RT-dPCR Master Mix at ₹223,115 for 192 reactions, while its 200-reaction 1-step RT-dPCR Master Mix is listed at ₹121,343.
That means a buyer should calculate:
Instrument cost + plates + master mix + assays + service + labor + maintenance
rather than comparing only the purchase price.
Who Are the Actual Buyers?
The main dPCR buyers include:
Pharmaceutical Companies
They use dPCR for biomarker research, rare mutation analysis, copy-number analysis, quality control and cell and gene therapy development.
Biotechnology Companies
Gene therapy and cell therapy developers are important users for applications such as viral-vector quantification, gene-editing analysis and residual DNA measurement.
CROs and CDMOs
These organizations need high utilization and throughput because one instrument can support testing for multiple pharmaceutical and biotech customers.
Clinical and Molecular Laboratories
Applications include oncology, liquid biopsy, infectious disease and genetic testing.
Universities and Research Institutes
These buyers are more likely to prioritize analytical flexibility, assay compatibility and manageable capital expenditure.
What Are Buyers Actually Comparing?
The purchase decision increasingly depends on:
- Instrument price
- Cost per sample
- Consumable pricing
- Throughput
- Multiplexing
- Hands-on time
- Automation
- Assay availability
- Software
- Service and maintenance
- Regulatory support
- Existing laboratory infrastructure
Thermo Fisher’s Absolute Q supports 4-color endpoint detection, approximately 90-minute runs, and sensitivity down to 1 copy under specified conditions.
Its broader ecosystem also includes predesigned TaqMan assays and custom assay design services.
Where Are the Key Buyers?
United States
The U.S. is an important buyer base because of its concentration of large pharmaceutical companies, biotechnology firms, CROs, gene therapy developers and research institutions.
Europe
Germany, the UK, France and Switzerland provide strong opportunities through pharmaceutical R&D, biotechnology and academic research.
Asia-Pacific
China, Japan, South Korea, Singapore and India are important locations for expanding molecular research, biotechnology and advanced-therapy activity.
For manufacturers, the opportunity should therefore be evaluated by buyer type, application and regional research infrastructure, rather than simply by country size.
What Are Digital PCR Companies Doing Differently?
Thermo Fisher
Thermo Fisher is emphasizing workflow simplification and automation. The Absolute Q requires approximately five minutes of hands-on time, while AutoRun configurations can support unattended operation for up to 72 hours.
Bio-Rad
Bio-Rad continues to build around its established droplet-based ddPCR ecosystem, giving laboratories a mature workflow for applications such as oncology, gene expression, copy-number analysis and advanced-therapy research.
The competitive difference is therefore moving beyond instrument price toward:
workflow + consumables + automation + assays + throughput + application support.
What Should Buyers Calculate Before Investing?
A better purchasing model is:
Total cost of ownership ÷ successful reportable results
A ₹96.96 lakh instrument with lower throughput or higher consumable requirements may not necessarily be cheaper over five years than a more expensive automated platform.
For high-volume pharma, CRO or CDMO laboratories, automation and labor savings can become more important than the initial capital cost.
For smaller research laboratories, the priority may instead be:
Lower upfront cost + flexible assays + lower recurring expenditure.
What Should Digital PCR Leaders Do Next?
Focus on Cost Per Result
Companies should make consumable economics as transparent as instrument pricing.
Expand Automation
High-volume laboratories need systems that reduce technician intervention and increase instrument utilization.
Build Application-Specific Solutions
Packages combining:
Instrument + assay + consumables + software + service
can create stronger value than selling the instrument alone.
Target Buyers by Application
Rather than using one sales strategy globally, companies should differentiate between:
Pharma → QC and advanced therapies
Biotech → gene and cell therapy
CRO/CDMO → throughput and utilization
Clinical labs → oncology and molecular testing
Research institutes → flexibility and analytical performance
What Should Digital PCR Leaders Track?
Leaders should continuously track:
- Instrument pricing
- Consumable pricing
- Sales and revenue
- Competitor investments
- Product launches
- Automation development
- Actual buyer organizations
- Buyer locations
- Application demand
- Regional opportunities
- Technology developments
The key question is not simply “Which dPCR instrument is cheaper?”
It is:
“Which platform provides the best combination of capital cost, consumable economics, throughput, automation and analytical performance for the target buyer?”
How Towards Healthcare Research & Consulting Can Add Value
Towards Healthcare Research & Consulting helps life-science technology leaders track:
- Company intelligence
- Device pricing
- Sales and revenue
- Competitor strategies
- Investment activity
- Actual buyer identification
- Buyer locations
- Technology intelligence
- Regional opportunities
- Strategic consulting
The objective is to connect pricing, competitors, buyers, applications, investments and regional opportunities so leaders can identify where to compete, whom to target and what their next strategic move should be.